Cardio Diagnostics Holdings Inc (CDIO) is a biotechnology company committed to enhancing cardiovascular health via cutting-edge diagnostic solutions. By leveraging advanced technologies, CDIO equips healthcare providers with critical tools for accurate assessment and management of cardiovascular conditions, thereby promoting better patient outcomes. With a strategic emphasis on personalized medicine, the company is well-positioned for significant growth, making it a compelling opportunity for institutional investors seeking to capitalize on innovations within the dynamic healthcare sector.
| Revenue (TTM) | 16,560 |
| Gross Profit (TTM) | 16,560 |
| EBITDA | $-6.27M |
| Operating Margin | -66598.00% |
| Return on Equity | -65.60% |
| Return on Assets | -38.00% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $3.01 |
| Price-to-Book | 0.66 |
| Price-to-Sales (TTM) | 343.02 |
| EV/Revenue | 23.01 |
| EV/EBITDA | -22.48 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 185.10% |
| Shares Outstanding | $2.96M |
| Float | $2.83M |
| % Insiders | 8.31% |
| % Institutions | 9.34% |
Volatility is currently contracting
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics today announced that Atlas Healthcare Physicians (AHP) will cover Cardio Diagnostics' tests, Epi+Gen CHD™ and PrecisionCHD™.
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics will exhibit at four upcoming national benefits conferences.
AUSTIN, Texas, May 20, 2026 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.
